Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico

Annals of Hepatology

Volumn 8, Issue 3, 2009, Pages 207-211

  Muñoz, Linda E ^a   Alcalá, Eliud G ^a   Cordero, Paula ^a   Martínez, Manuel A ^b   Vázquez, Nathalie Y ^a   Galindo, Susana ^b   Mendoza, Eduardo ^b   Segura, José J ^b  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Albumin; Cirrhosis; Hepatorenal syndrome; Serum creatinine; Terlipressin

Indexed keywords

ALBUMIN; GLYVERASE; TERLIPRESSIN; UNCLASSIFIED DRUG; ALBUMINOID; CREATININE; DRUG DERIVATIVE; LYPRESSIN; VASOCONSTRICTOR AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL PERITONITIS; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LUNG EDEMA; MALE; MEXICO; SURVIVAL TIME; TACHYCARDIA; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; BLOOD; DRUG COMBINATION; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ALBUMINS; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LYPRESSIN; MALE; MEXICO; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 77952490875     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31767-3     Document Type: Article

References (27)

1. Arroyo V, Fernández J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 81-95.
2. Ramírez B, Galindo S, Pérez JL. Síndrome Hepatorrenal. In: Muñoz L (ed.). Hepatología: Desde la biologia molecular al diagnostico, tratamiento y prevención. México: Editorial McGraw-Hill; 2007, p. 321-327.
3. Porcel A, Díaz F, Rendon P, Macias M, Martín-Herrera L, Gi-rón-González JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323-328.
4. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008; 48: S93-S103.
5. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-1318.
6. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, Bataller R, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48.
7. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatol 2007; 47: 499-505.
8. Angeli P. Review article: prognosis of hepatorenal syndrome-has it changed with current practice? Aliment Pharmacol Ther 2004; 20(Suppl. 3): 44-46.
9. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salme-ron JM, Jimenez W. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
10. Sanyal A, Boyer T, García-Tsao G. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-1368.
11. Martín-Llahí M, Pepin MN, Guevara M, Díaz F, Torre A, Mo-nescillo A, Soriano G, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study. Gastroenterology 2008; 134: 1352-1359.
12. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24: 935-944.
13. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-948.
14. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin S. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled trial. J Gastroenterol Hepatol 2003; 18: 152-156.
15. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D. Beneficial effects of the 2-day administration of terlipres-sin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-570.
16. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006; Issue 4: CD005162.
17. Therapondos G, Stanley A, Hayes P. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: Pilot study. J Gastroenterol Hepatol 2004; 19: 73-77.
18. Krag A, Moller S, Henriksen J, Holstein-Rathlou N. Terlipressin improves renal function in patients with cirrhosis and asci-tes without hepatorenal syndrome. Hepatology 2007; 46: 1864-1870.
19. Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Moller S, Bendt-sen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 2004; 5: 486-492.
20. Gines P, Guevara M. Hyponatremia in cirrhosis: Pathogene-sis, clinical significance, and management. Hepatology 2008; 48: 1002-1010.
21. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002; 17: 739-747.
22. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, Lebrec D, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: A retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-888.
23. Arroyo V. Review article: Hepatorenal syndrome-how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther 2004; 20(Suppl. 3): 49-54.
24. Gines P, Torre A, Terra C, Guevara M. Review article: Pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004; 20(Suppl. 3): 57-62.
25. Gines P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827.
26. Sandhu B, Sanyal A. Management of ascites in cirrhosis. Clin Liver Dis 2005; 9: 715-732.
27. Moller S, Henriksen JH. Review article: Pathogenesis and patho-physiology of hepatorenal syndrome-is there scope for prevention? Aliment Pharmacol Ther 2004; 20(Suppl. 3): 31-41.